Radboud university medical center
Radboudumc Technology Center Clinical Studies

P.O. Box 9101, 6500 HB Nijmegen
The Netherlands
Internal postal code 392
Philips van Leydenlaan 15
Radboudumc entrance west, route 392
T +31 24 366 83 33

Manager Policy, Quality and Support
mrs. J.A.H. Droste, PhD
rtcclinicalstudies@radboudumc.nl
www.radboudumc.nl

Dutch Chamber of Commerce
trade register 80262783

392
European Medicines Agency
Domenico Scarlattilaan 6,
1083 HS Amsterdam

Date	Our reference	Page
30 June 2022	AN/GR	1 of 1
Your reference	Contact	
	RTC Clinical Studies	

Subject
Results posting of EudraCT **2007-004620-20**; "Persantin Preceding PCI"

Dear EMA,

On behalf of the Prof. dr. G.A.P.J.M. Rongen as Principal Investigator of this study, I hereby confirm that the following clinical trial protocol: "Persantin Preceding PCI" with EudraCT number 2007-004620-20, **was preliminary terminated after inclusion of 10 patients.** The reason for this was **lack of feasibility, both in recruitment and performance of the trial**. This trial was replaced by another study investigating a similar dose of dipyridamole in patients scheduled for coronary bypass surgery (EudraCT number: 2009-014299-22; study closed September 2012). This trial has been published (https://doi.org/10.1002/cpt.106).

Dipyridamole appeared to be safe in this study population which is similar to the one proposed for the Persantin Prceceding PCI study.

The Declaration End of Trial Form B7 reported "Completed", but this should be "**Prematurely Ended**".

We hope this information is sufficient to finalize results posting.

With kind regards,

Arjan Nooteboom,
Research Consultant at RTC Clinical Studies
Radboudumc
rtcclinicalstudies@radboudumc.nl

cc Prof.dr. G.A.P.J.M Rongen